Difference between revisions of "Lobaplatin (D-19466)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 4: | Line 4: | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. |
==Also known as== | ==Also known as== | ||
Line 16: | Line 16: | ||
[[Category:Platinum agents]] | [[Category:Platinum agents]] | ||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
− | [[Category:NMPA approved | + | |
+ | [[Category:Nasopharyngeal carcinoma medications]] | ||
+ | |||
+ | [[Category:NMPA approved in 2005]] |
Latest revision as of 01:06, 29 June 2024
General information
Class/mechanism: Third-generation platinum compound with DNA alkylating activity, producing interstrand DNA crosslinks, which result in apoptosis.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
Also known as
- Code name: D-19466